Advances in the Pharmacogenomics of Adverse Drug Reactions. (Q38663764)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650062%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Advances in the Pharmacogenomics of Adverse Drug Reactions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650062%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650062%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Daniel Carr

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650062%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Susannah L Collins

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650062%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

1 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650062%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650062%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650062%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650062%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

15-27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26650062%20AND%20SRC:MED&resulttype=core&format=json

Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

The Sequence of the Human Genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

21 January 2018

Bring on the biomarkers

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Clinical perspectives in drug safety and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Pharmacogenomics of adverse drug reactions: implementing personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Joining the DoTS: new approach to classifying adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

The International HapMap Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

The NHGRI GWAS Catalog, a curated resource of SNP-trait associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

A map of human genome variation from population-scale sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Personalized pharmacogenomics: predicting efficacy and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

A randomized trial of genotype-guided dosing of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Candidate gene approach for pharmacogenetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Progress and promise of genome-wide association studies for human complex trait genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Genome-wide association studies in pharmacogenomics: successes and lessons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Performance of HLA allele prediction methods in African Americans for class II genes HLA-DRB1, -DQB1, and -DPB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

HIBAG--HLA genotype imputation with attribute bagging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Multi-population classical HLA type imputation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

The use of imputed values in the meta-analysis of genome-wide association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Genotype imputation for genome-wide association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Fast and accurate genotype imputation in genome-wide association studies through pre-phasing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

A linear complexity phasing method for thousands of genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Imputation without doing imputation: a new method for the detection of non-genotyped causal variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Simultaneous analysis of all SNPs in genome-wide and re-sequencing association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Rare-variant association analysis: study designs and statistical tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Deciphering next-generation pharmacogenomics: an information technology perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Interpretation of genetic association studies in complex disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Implication of next-generation sequencing on association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Early detection of paracetamol toxicity using circulating liver microRNA and markers of cell necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Differential microRNA regulation of HLA-C expression and its association with HIV control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Could MicroRNA polymorphisms influence warfarin dosing? A pharmacogenetics study on mir133 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Genotyping of drug targets: a method to predict adverse drug reactions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Oral anticoagulation: a critique of recent advances and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

A pharmacogenetic versus a clinical algorithm for warfarin dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Pharmacogenetics: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

The innovative use of a large-scale industry biomedical consortium to research the genetic basis of drug induced serious adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Phenotype standardization for immune-mediated drug-induced skin injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Phenotype standardization for statin-induced myotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Phenotype standardization of angioedema in the head and neck region caused by agents acting on the angiotensin system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Adding pharmacogenetics information to drug labels: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Pharmacogenetics: from bench to byte--an update of guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Pharmacogenetics of idiosyncratic adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Integrated electrochemical microsystems for genetic detection of pathogens at the point of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

The current and future state of companion diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Genetic predisposition of life-threatening antiepileptic-induced skin reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Anticonvulsant hypersensitivity syndrome: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Impact of phenytoin therapy on the skin and skin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Flucloxacillin-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Antituberculosis drug-induced hepatotoxicity: concise up-to-date review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

A review of the gastrointestinal safety data--a gastroenterologist's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Renal toxicity of therapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

21 January 2018

Indinavir crystalluria

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Ophthalmic adverse drug reactions to systemic drugs: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Ocular toxicity from systemically administered xenobiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Adverse reactions to duloxetine in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Review article: metoclopramide and tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Neuronal toxicity of efavirenz: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

A systematic review of statin-induced muscle problems in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Colchicine myotoxicity: case reports and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Genetics of acquired long QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

New developments in aminoglycoside therapy and ototoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Co-amoxiclav jaundice: clinical and histological features and HLA class II association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Codeine intoxication associated with ultrarapid CYP2D6 metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Hemolysis and methemoglobinemia secondary to rasburicase administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

SLCO1B1 Polymorphisms and Statin-Induced Myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Personalized pharmacogenomics profiling using whole-genome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0367-8

Voriconazole-associated phototoxicity

21 January 2018

1 reference

12 December 2020

Pharmacogenomics: Current State-of-the-Art

1 reference

12 December 2020

Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01

1 reference

12 December 2020

HLA-Cw8 primarily associated with hypersensitivity to nevirapine

1 reference

12 December 2020

Upregulation of miR-18a-5p contributes to epidermal necrolysis in severe drug eruptions

1 reference

12 December 2020

HLA associations in clozapine-induced agranulocytosis

1 reference

12 December 2020

Implementation and utilization of genetic testing in personalized medicine

1 reference

12 December 2020

Serum miR-124 up-regulation as a disease marker of toxic epidermal necrolysis.

1 reference

12 December 2020

The haemolytic effect of various regimens of primaquine with chloroquine in American Negroes with G6PD deficiency and the lack of an effect of various antimalarial suppressive agents on erythrocyte metabolism

1 reference

12 December 2020

Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues

1 reference

12 December 2020

Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance

1 reference

12 December 2020

Dapsone-induced hemolytic anemia: role of glucose-6-phosphate dehydrogenase in the hemolytic response of rat erythrocytes to N-hydroxydapsone.

1 reference

12 December 2020

Circulating microRNAs as potential markers of human drug-induced liver injury

1 reference

12 December 2020

Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore

1 reference

12 December 2020

Preemptive genotyping trialed to prevent adverse drug reactions

1 reference

12 December 2020